Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

FDA Clears Guardant360 CDx as Companion Diagnostic for Imlunestrant in ESR1-Mutated Breast Cancer

September 29th 2025

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice

September 28th 2025

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

Revumenib Joins NCCN Guidelines for NPM1-Mutated R/R Acute Myeloid Leukemia

September 26th 2025

The NCCN has issued a category 2A recommendation for revumenib in relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC

September 25th 2025

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 9/14

September 21st 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

Taletrectinib Wins Japanese Approval for ROS1+ Advanced NSCLC

September 19th 2025

Taletrectinib was approved in Japan for advanced non–small cell lung cancer harboring ROS1 fusions.

Rezatapopt Elicits Responses in Several Solid Tumors Harboring a TP53 Y220C Mutation

September 15th 2025

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

IDE397 Plus Sacituzumab Govitecan Elicits Responses in MTAP-Deletion Urothelial Cancer

September 15th 2025

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC

September 8th 2025

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

TT125-802 Earns FDA Fast Track Designations for EGFR+ and KRAS G12C+ Advanced NSCLC

September 1st 2025

TT125-802 has received FDA fast track designations in EGFR+ and KRAS G12C+ advanced NSCLC.

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.